
    
      This is a single arm, open-label, multicentre, phase II trial in which patients with
      metastatic gastric or GEJ adenocarcinoma will be treated with the combination of irinotecan,
      capecitabine, and oxaliplatin (IXO).Patients will receive the combination of irinotecan,
      capecitabine, and oxaliplatin at the recommended phase II dose and sequence determined by the
      completed phase I trial. Patients will be treated on study until disease progression,
      overwhelming toxicity, or consent withdrawal.
    
  